Brain metastases in patient with prostate cancer found in 18F-choline PET/CT

Giżewska, Agnieszka; Witkowska-Patena, Ewa; Stembrowicz-Nowakowska, Zofia; Buraczewska, Agnieszka; Dziuk, Mirosław

doi:10.5603/nmr.2015.0010

Cited by 10 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[48][49][50][51][52][53][54] Choline derivatives (eg, 18 F-choline), which are in use for the diagnosis of recurrent prostate cancer, have also been reported to label BM. 55,56 Animal studies have found that PET imaging using agents targeting the mitochondrial translocator protein (TSPO), which is upregulated on activated microglia, may be helpful for BM detection at an early stage of development. 57 Despite promising results, experience with these tracers is based mainly on single cases in patients with BM, and their usefulness needs to be confirmed in larger studies.…”

Section: Other Pet Tracersmentioning

confidence: 99%

PET imaging in patients with brain metastasis—report of the RANO/PET group

et al. 2019

View full text Add to dashboard Cite

Brain metastases (BM) from extracranial cancer are associated with significant morbidity and mortality. Effective local treatment options are stereotactic radiotherapy, including radiosurgery or fractionated external beam radiotherapy, and surgical resection. The use of systemic treatment for intracranial disease control also is improving. BM diagnosis, treatment planning, and follow-up is most often based on contrast-enhanced magnetic resonance imaging (MRI). However, anatomic imaging modalities including standard MRI have limitations in accurately characterizing posttherapeutic reactive changes and treatment response. Molecular imaging techniques such as positron emission tomography (PET) characterize specific metabolic and cellular features of metastases, potentially providing clinically relevant information supplementing anatomic MRI. Here, the Response Assessment in Neuro-Oncology working group provides recommendations for the use of PET imaging in the clinical management of patients with BM based on evidence from studies validated by histology and/or clinical outcome.

show abstract

Section: Other Pet Tracersmentioning

confidence: 99%

PET imaging in patients with brain metastasis—report of the RANO/PET group

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Several other radiotracers have been used in clinical assessments of BM, such as sodium [ 18 F]fluoride (Na[ 18 F]F) to detect BM and study tumor responses after chemotherapy, 99 [ 18 F]-fluorocholine to detect BM and distinguish them from other brain tumors, 100 rubidium ( 82 Rb), 101 [ 68 Ga]Ga-PSMA-11, 102 and [ 18 F]-PSMA-1007 103 to detect BM, and [ 18 F]fluoromisonidazole ([ 18 F]FMISO) to study intra-tumoral hypoxia. 104 …”

Section: Positron Emission Tomography (Pet)mentioning

confidence: 99%

Current landscape and future perspectives in preclinical MR and PET imaging of brain metastasis

Aasen

Espedal

Keunen

et al. 2021

Neuro-Oncology Advances

View full text Add to dashboard Cite

Brain metastasis (BM) is a major cause of cancer patient morbidity. Clinical magnetic resonance imaging (MRI) and positron emission tomography (PET) represent important resources to assess tumor progression and treatment responses.In preclinical research, anatomical MRI and to some extent functional MRI have frequently been used to assess tumor progression. In contrast, PET has only to a limited extent been used in animal BM research. A considerable culprit is that results from most preclinical studies have showed little impact on the implementation of new treatment strategies in the clinic. This emphasizes the need for the development of robust, high-quality preclinical imaging strategies with potential for clinical translation.This review focuses on advanced preclinical MRI and PET imaging methods for BM, describing their applications in the context of what has been done in the clinic. The strengths and shortcomings of each technology are presented, and recommendations for future directions in the development of the individual imaging modalities are suggested. Finally, we highlight recent developments in quantitative MRI and PET, the use of radiomics and multimodal imaging, and the need for a standardization of imaging technologies and protocols between preclinical centers.

show abstract

“…Recently, there has been a trend showing an increase in the number of PCa cases with a reported metastatic brain lesion. Tis brings to light the numerous challenges we face in terms of properly understanding, diagnosing, and managing PCa patients with BMs [14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33]. Given the lack of knowledge regarding the issue of metastatic brain lesions in PCa, we decided to comprehensively and systematically review the latest evidence regarding the clinical manifestations, diagnosis, treatment, and prognosis of the BMs in PCa.…”

Section: Introductionmentioning

confidence: 99%

The Clinical, Diagnostic, Therapeutic, and Prognostic Characteristics of Brain Metastases in Prostate Cancer: A Systematic Review

et al. 2022

View full text Add to dashboard Cite

Aim. Prostate cancer (PCa) is the second most common nonskin malignancy and the second most common cause of cancer-related deaths in men. The most common site of metastasis in PCa is the axial skeleton which may lead to back pain or pathological fractures. Hematogenous spread to the brain and involvement of the central nervous system (CNS) are a rare occurrence. However, failed androgen deprivation therapy (ADT) may facilitate such a spread resulting in an advanced metastatic stage of PCa, which carries a poor prognosis. Methods. In this systematic review, we searched the PubMed, Scopus, and Web of Science online databases based on the PRISMA guideline and used all the medical subject headings (MeSH) in terms of the following search line: (“Brain Neoplasms” OR “Central Nervous System Neoplasms”) and (“Prostatic Neoplasms” OR “Prostate”). Related studies were identified and reviewed. Results. A total of 59 eligible studies (902 patients) were included in this systematic review. In order to gain a deeper understanding, we extracted and presented the data from included articles based on clinical manifestations, diagnostic methods, therapeutic approaches, and prognostic status of PCa patients having BMs. Conclusion. We have demonstrated the current knowledge regarding the mechanism, clinical manifestations, diagnostic methods, therapeutic approaches, and prognosis of BMs in PCa. These data shed more light on the way to help clinicians and physicians to understand, diagnose, and manage BMs in PCa patients better.

show abstract

Brain metastases in patient with prostate cancer found in 18F-choline PET/CT

Cited by 10 publications

References 15 publications

PET imaging in patients with brain metastasis—report of the RANO/PET group

PET imaging in patients with brain metastasis—report of the RANO/PET group

Current landscape and future perspectives in preclinical MR and PET imaging of brain metastasis

The Clinical, Diagnostic, Therapeutic, and Prognostic Characteristics of Brain Metastases in Prostate Cancer: A Systematic Review

Contact Info

Product

Resources

About